Shanghai Fosun Pharmaceutical Group

Fosun Kite Biotechnology names Richard L. Wang chief executive officer

Monday, March 6, 2017

Kite Pharma announced that Richard L. Wang, Ph.D. will be appointed chief executive officer of Fosun Kite Biotechnology Co., Ltd, the company’s 50/50 owned joint venture in China with Shanghai Fosun Pharmaceutical (Group) Co., Ltd.The companies announced the formation of the joint venture in early 2017 to develop, manufacture and commercialize autologous T-cell therapies to treat cancer in China, including Kite’s lead cell therapy product candidate, axicabtagene ciloleucel. Final registration of the joint venture is ongoing.

[Read More]

Kite Pharma, Fosun Pharma establish joint venture in China

Tuesday, January 10, 2017

Kite Pharma and Shanghai Fosun Pharmaceutical have announced a joint venture, Fosun Pharma Kite Biotechnology (company name subject to the approval of relevant registration authorities) to develop, manufacture and commercialize axicabtagene ciloleucel in China with the option to include additional products, including two T cell receptor (TCR) product candidates from Kite. Axicabtagene ciloleucel (KTE-C19), Kite’s lead product candidate, is an investigational chimeric antigen receptor (CAR) T-cell therapy under development for the treatment of B-cell lymphomas and leukemias.

[Read More]

Fosun Pharma, HOPU Investments, CEL Healthcare Fund, WuXi PharmaTech to acquire Ambrx

Friday, May 22, 2015

A consortium—consisting of entities affiliated with Shanghai Fosun Pharmaceutical Group, HOPU InvestmentsChina Everbright’s Healthcare Fund and WuXi PharmaTech—has signed a merger agreement to acquire Ambrx. The transaction is expected to close in the second quarter of 2015, subject to receipt of certain regulatory approvals and satisfaction of customary closing conditions.

[Read More]